Abstract
Aim Coronavirus disease 2019 (COVID-19) has rapidly become the most severe public health issue all over the world. Despite acute respiratory failure, liver dysfunction has also been observed in clinical settings This study aimed to investigate the factors involved with hepatic injury in COVID-19 patients.
Methods A total of 26 hospitalized patients who were diagnosed with COVID-19 treated at Beijing You’an Hospital were retrospectively analyzed. According to the diagnostic criteria, they were divided into mild group (n=3), ordinary group (n=6), serious group (n=11) and critical group (n=6). Blood count, blood chemistry, coagulation test, liver and renal function, C-reactive protein, procalcitonin, lactic acid, cardiac markers and arterial partial pressure was compared between these groups. Independent risk factors of ALT increase was selected.
Results There were 8 patients with ALT elevation in the patients with COVID-19, accounting for 30.8% (8/26). There was no difference in sex ratio between normal and elevated ALT population, and there was an increasing trend in age. The CRP index was significantly higher in the population with elevated ALT, and the increase of CRP was independently related to ALT level, and the OR value was 1.023 (P = 0.024).
Conclusions COVID-19 related hepatic injury may be a result of cytokine storm syndrome, a positive correlative relationship between the increase of CRP and liver injury. Early detection and timely treatment of hepatic injury is necessary.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Key R&D Program of China（No.2017YFA0103000）; National Science and Technology Key Project on “Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment”（NO. 2017ZX10203201-005）;Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support （NO.ZYLX201806）
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available.
